CAR-T cell therapy for autoimmune diseases that resist treatment
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy, Skin clinical trials.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lupus, scleroderma, inflammatory myositis, rheumatoid arthritis, neuromyelitis optica, multiple sclerosis, myasthenia gravis, or antiphospholipid syndrome.
- You have tried at least two standard treatments for your condition but they did not work or caused serious side effects.
- You are between 18 and 80 years old (if 75–80, a special health check is needed).
- Your heart, lungs, and liver are working well enough, with no unstable heart disease or severe lung problems.
- You have not had rituximab in the last 4 months, and you do not have active infections like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new cell therapy called C-CAR168, which uses a patient's own immune cells to target and potentially reset the immune system to treat conditions like multiple sclerosis, lupus, and myasthenia gravis. It's for people whose disease has not improved with standard treatments.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.